EyeBiotech, a London, UK-based clinical-stage ophthalmology biotechnology company, raised additional $65M in Series A funding.
The round, which brought the total amount to $130M, saw participation form Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC and from existing investors SV Health Investors, Jeito Capital, Samsara Biocapital and MRL Ventures Fund.
The company intends to use the proceeds from the funding to accelerate its clinical development program and further build out its innovative retina pipeline.
Founded in August 2021 by David Guyer, M.D., and Tony Adamis, M.D., Eyebiotech is a clinical-stage, ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases. It has a team with experience in ophthalmology drug development. With operations in the United States and the United Kingdom, EyeBio is building a pipeline of ocular therapies that combine scientifically robust targets with translational approaches.
In addition to the Series A expansion, EyeBio announced the completion of enrollment into the multiple ascending dose (MAD) portion of AMARONE, the Phase 1b/2a clinical trial of Restoret in patients with diabetic macular edema (DME) and neovascular age related macular degeneration (NVAMD). Restoret is an investigational, intravitreally delivered, tri-specific antibody that acts as an agonist of the Wnt signaling pathway. It is designed to resolve residual fluid in the retina with the goal of improving visual acuity in individuals with NVAMD and DME, as well as other retinal diseases of permeability.
FinSMEs
14/11/2023